Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF

J. Tužil, T. Mlčoch, J. Závada, M. Svoboda, K. Pavelka, T. Doležal

. 2022 ; 61 (6) : 2295-2306. [pub] 20220530

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018294

OBJECTIVE Achieving targeted disease activity DA is the primary therapeutic strategy in RA Point measurements of DA are done at out patient visits however true DA between visits remains unobserved This study sought to describe and validate a new outcome measure i e time in remission TIR METHODS Patients were enrolled in the Czech ATTRA RA registry TIR was calculated using linear interpol

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018294
003      
CZ-PrNML
005      
20221026131925.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keab737 $2 doi
035    __
$a (PubMed)34599798
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tužil, Jan $u Institute of Health Economics and Technology Assessment $u 1st Faculty of Medicine, Charles University in Prague $1 https://orcid.org/0000000271824010
245    10
$a Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF / $c J. Tužil, T. Mlčoch, J. Závada, M. Svoboda, K. Pavelka, T. Doležal
520    9_
$a OBJECTIVE: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This study sought to describe and validate a new outcome measure, i.e. time in remission (TIR). METHODS: Patients were enrolled in the Czech ATTRA-RA registry. TIR was calculated using li $a OBJECTIVE: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This study sought to describe and validate a new outcome measure, i.e. time in remission (TIR). METHODS: Patients were enrolled in the Czech ATTRA-RA registry. TIR was calculated using linear interpolation of the DAS28-ESR determined at outpatient visits. Correlation coefficients were computed between TIR and DAS28-CRP, HAQ, Simple Disease Activity Index (SDAI), patient global assessment (PGA) and physician global assessment (PhGA). Using logistic regression, TIR was used as a predictor of remission (SDAI ≤3.3) and non-disability (HAQ <0.5). The predictive value of TIR was compared with point and sustained remission using the cross-validated area under receiver-operating curves. RESULTS: Since 2010, 2618 RA patients started anti-TNF therapy and were followed until 2020 or until treatment discontinuation. During the first 6 months of therapy, 56% of patients had no remission (TIR = 0), and 22% of patients reached sustained remission (TIR = 1), while 22% of patients had point remissions with 0 < TIR < 1. EULAR good responders and moderate/non-responders spent 64 ± 42% and 6 ± 18% of time in remission, respectively. The mean TIR grew during the follow-up and was correlated with DAS28-CRP, SDAI, HAQ, PGA, and PhGA (P < 0.0001). TIR at 3 and 6 months predicted remission (SDAI ≤3.3) and non-disability (HAQ <0.5) at 13 and 19 months better than point or sustained remission. CONCLUSIONS: TIR is an intuitive way of estimating unobserved DA between scheduled visits; its calculation only requires two consecutive DA values (https://www.medevio.cz/tir-calculator/). TIR is a valid predictor of RA outcomes. $a OBJECTIVE Achieving targeted disease activity DA is the primary therapeutic strategy in RA Point measurements of DA are done at out patient visits however true DA between visits remains unobserved This study sought to describe and validate a new outcome measure i e time in remission TIR METHODS Patients were enrolled in the Czech ATTRA RA registry TIR was calculated using linear interpol
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a revmatoidní artritida $x farmakoterapie $7 D001172
650    _2
$a lidé $7 D006801
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a prospektivní studie $7 D011446
650    _2
$a prostaglandiny A $x terapeutické užití $7 D011454
650    _2
$a indukce remise $7 D012074
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory TNF $7 D000079424
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mlčoch, Tomáš $u Institute of Health Economics and Technology Assessment $1 https://orcid.org/0000000277168819
700    1_
$a Závada, Jakub $u 1st Faculty of Medicine, Charles University in Prague $u Institute of Rheumatology, Prague $1 https://orcid.org/0000000298026545 $7 xx0160054
700    1_
$a Svoboda, Michal $u Institute of Biostatistics and Analyses, Ltd, Spinoff Company of the Faculty of Medicine of the Masaryk University, Brno $1 https://orcid.org/0000000303122524
700    1_
$a Pavelka, Karel $u 1st Faculty of Medicine, Charles University in Prague $u Institute of Rheumatology, Prague $1 https://orcid.org/0000000319528422 $7 jn99240000847
700    1_
$a Doležal, Tomáš, $u Institute of Health Economics and Technology Assessment $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $d 1972- $7 xx0070153
773    0_
$w MED00011379 $t Rheumatology $x 1462-0332 $g Roč. 61, č. 6 (2022), s. 2295-2306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34599798 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20221026131922 $b ABA008
999    __
$a ok $b bmc $g 1822071 $s 1169537
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 61 $c 6 $d 2295-2306 $e 20220530 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace